Table 5.
Comparison of treatment outcome between groups 1 and 2
| Treatment outcome | All patients | Group 1 | Group 2 | P value |
|---|---|---|---|---|
| Patients | 63 | 17 | 46 | |
| Fibroid volumea | ||||
| Baseline | 171.7 ± 149.3 (6.0–794.0) | 179.4 ± 176.1 (37.0–794.0) | 168.9 ± 140.2 (6.0–637.0) | 0.806 |
| 6 months | 92.4 ± 93.4 (4.0–578.0) | 87.8 ± 68.6 (11.0–295.0) | 94.1 ± 101.6 (4.0–578.0) | 0.813 |
| Reduction ratio (6 months) | 0.44 ± 0.22 (−0.21–0.84) | 0.45 ± 0.27 (−0.03–0.80) | 0.43 ± 0.21 (−0.21–0.84) | 0.747 |
| Symptom severity scoreb | ||||
| Baseline | 53.5 ± 16.5 (21.9–93.8) | 55.0 ± 15.9 (31.2–87.5) | 53.0 ± 16.5 (21.9–93.8) | 0.672 |
| 6 months | 13.0 ± 19.8 (0.0–100.0) | 16.5 ± 21.9 (0.0–62.5) | 11.7 ± 19.0 (0.0–100.0) | 0.391 |
| Improvement ratio (6 months) | 0.77 ± 0.31 (−0.2–1.0) | 0.7 ± 0.39 (−0.2–1.0) | 0.79 ± 0.28 (−0.07–1.0) | 0.055 |
Values in parentheses represent ranges
aLargest treated fibroid only
bTransformed symptom severe score (SSS) can range from 0 to 100